Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06013137 · ClinicalTrials.gov registry record · NA

Chatbot for Depression, Anxiety, and Eating Disorders

A NA study of Depression and Anxiety, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
NA
Development phase
210
Enrollment target
1
Study location

NCT06013137: Completed NA study of Depression and Anxiety, sponsored by Dartmouth-Hitchcock Medical Center.

NCT06013137 is a NA study of Depression and Anxiety that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 210 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06013137, a NA study of Depression and Anxiety, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
NA
Development phase
210 participants
Enrollment target
1
Study location

Study Summary

The research team would like to test how efficacious an artificial intelligence chatbot is in delivering supportive behavioral interventions in populations with anxiety, depression, or eating concerns.

Primary Outcome

Anxiety symptoms will be measured with the GAD-IV.

Interventions

  • OTHER Therabot

Study Locations (1)

New Hampshire

  • Dartmouth College - Lebanon

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2024-03-11
Est. Completion 2024-08-30
Phase NA
Dartmouth-Hitchcock Medical Center

427 total trials

What the finished NCT06013137 record still lists

NCT06013137 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (73% lower).

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Therabot is the first listed.

NCT06013137 reports a single indexed study location in New Hampshire.

Frequently Asked Questions

What is clinical trial NCT06013137 about?

NCT06013137 is a clinical study titled "Chatbot for Depression, Anxiety, and Eating Disorders". The research team would like to test how efficacious an artificial intelligence chatbot is in delivering supportive behavioral interventions in populations with anxiety, depression, or eating concerns.

What is the current status of trial NCT06013137?

This trial is currently completed. It is a NA study. The enrollment target is 210 participants. The study started on 2024-03-11. Estimated completion is 2024-08-30.

What conditions does trial NCT06013137 study?

This clinical trial studies the following conditions: Depression, Anxiety, Eating Disorders.

What interventions are being tested in trial NCT06013137?

The interventions under investigation include: Therabot (OTHER).

Who is sponsoring clinical trial NCT06013137?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06013137 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06013137's enrollment target sits among peer trials

210 202nd of 679 higher than 477 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

  • NCT03544489 · 210 participants · Phase 2

    Effectiveness of Exercise After an ICD

  • NCT04408430 · 210 participants · NA

    The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT06013137, the US trial registry maintained by the National Library of Medicine. NCT06013137 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.